Literature DB >> 9528837

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

A Knoop1, P A Andreasen, J A Andersen, S Hansen, A V Laenkholm, A C Simonsen, J Andersen, J Overgaard, C Rose.   

Abstract

The uPA-mediated pathway of plasminogen activation is central to cancer metastasis. Whether uPA and PAI-1 are related to local recurrence, metastatic spread or both is not clear. We present a retrospective study of 429 primary breast cancer patients with a median follow-up of 5.1 years, in which the levels of uPA and PAI-1 in tumour extracts were analysed by means of an enzyme-linked immunosorbent assay. The median values of uPA and PAI-1, which were used as cut-off points, were 4.5 and 11.1 ng mg(-1) protein respectively. The levels of uPA and PAI-1 were correlated with tumour size, degree of anaplasia, steroid receptor status and number of positive nodes. Patients with high content of either uPA or PAI-1 had increased risk of relapse and death. We demonstrated an independent ability of PAI-1 to predict distant metastasis (relative risk 1.7, confidence limits 1.22 and 2.46) and that neither uPA nor PAI-1 provided any information regarding local recurrence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528837      PMCID: PMC2150087          DOI: 10.1038/bjc.1998.154

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

Review 1.  Plasminogen activator inhibitors: hormonally regulated serpins.

Authors:  P A Andreasen; B Georg; L R Lund; A Riccio; S N Stacey
Journal:  Mol Cell Endocrinol       Date:  1990-01-02       Impact factor: 4.102

2.  Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin.

Authors:  J Grøndahl-Hansen; E Ralfkiaer; L S Nielsen; P Kristensen; G Frentz; K Danø
Journal:  J Invest Dermatol       Date:  1987-01       Impact factor: 8.551

3.  Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.

Authors:  L S Nielsen; J Grøndahl-Hansen; P A Andreasen; L Skriver; J Zeuthen; K Danø
Journal:  J Immunoassay       Date:  1986

4.  Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.

Authors:  S M Thorpe
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 6.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

7.  Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.

Authors:  L S Nielsen; P A Andreasen; J Grøndahl-Hansen; J Y Huang; P Kristensen; K Danø
Journal:  Thromb Haemost       Date:  1986-04-30       Impact factor: 5.249

8.  The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays.

Authors:  J Andersen; S M Thorpe; W J King; C Rose; I Christensen; B B Rasmussen; H S Poulsen
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

9.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

10.  Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.

Authors:  J Pöllänen; O Saksela; E M Salonen; P Andreasen; L Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1987-04       Impact factor: 10.539

View more
  20 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Feline mammary adenocarcinoma: tumor size as a prognostic indicator.

Authors:  Jodi R Viste; Sherry L Myers; Baljit Singh; Elemir Simko
Journal:  Can Vet J       Date:  2002-01       Impact factor: 1.008

3.  A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

Authors:  Tongjian Cai; Xueyong Li; Jin Ding; Wenjing Luo; Jingxia Li; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

Review 4.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

5.  Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Authors:  Daniel Miotto Dupont; Jeppe Buur Madsen; Roland Karl Hartmann; Bertrand Tavitian; Frédéric Ducongé; Jørgen Kjems; Peter André Andreasen
Journal:  RNA       Date:  2010-10-20       Impact factor: 4.942

6.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

7.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

8.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

9.  Deregulated activation of matriptase in breast cancer cells.

Authors:  Christelle M Benaud; Michael Oberst; Robert B Dickson; Chen-Yong Lin
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.